|
08-07-2011, 06:12 AM
|
#1
|
Senior Member
Join Date: Aug 2003
Location: Morris, IL
Posts: 3,507
|
List of Drugs in Short Supply...Xeloda, Cisplatin
Hard to read but surprised to find common chemo drugs on here....Capecitabine (Xeloda), Cisplatin, Metformin, ...not sad to see Dexamethasone on here.....not my favorite. If you have questions, you should ask your Dr or pharmacist about the recalls/shortages.
Drug Shortages: Current Drugs
ASHP and its partners works to keep the public informed of the most current drug shortages. Shortages can adversely affect drug therapy, compromise or delay medical procedures, and result in medication errors.
Current Drug Shortage Bulletins
RSS Learn About RSS Sort by: Generic Name | Revision Date
Generic NameRevision Date Acetaminophen Suppositories July 18, 2011 Acetazolamide InjectionJuly 22, 2011 Acetylcysteine Inhalation Solution July 22, 2011 Acyclovir InjectionJuly 27, 2011 Acyclovir Capsules and TabletsJuly 12, 2011 Alcohol Dehydrated Injection (Ethanol) August 05, 2011 Alprostadil ProductsJune 28, 2011 Amikacin InjectionJuly 20, 2011 Aminocaproic Acid Injection July 22, 2011 Aminophylline InjectionJuly 22, 2011 Amiodarone Hydrochloride InjectionJuly 14, 2011 Ammonium Chloride Injection July 20, 2011 Ammonium Molybdate Injection July 22, 2011 Amphetamine Mixed Salts, Extended-Release CapsulesJuly 18, 2011 Ampicillin Sulbactam July 28, 2011 Arginine 10% Injection August 02, 2011 Aripiprazole Injection July 26, 2011 Ascorbic Acid Injection July 20, 2011 Atropine Sulfate InjectionAugust 02, 2011 Azathioprine Injection August 03, 2011 Azithromycin Injection July 28, 2011 Betamethasone Acetate and Sodium Phosphate InjectionAugust 02, 2011 Bisacodyl Enema July 27, 2011 Black Widow Antivenin (Latrodectus Mactans) July 26, 2011 Bleomycin InjectionAugust 03, 2011 Budesonide Inhalation Suspension June 28, 2011 Bupivacaine with epinephrine injection July 28, 2011 Buprenorphine Injection July 22, 2011 Busulfan July 12, 2011 Butorphanol Injection August 02, 2011 Caffeine/Caffeine and Sodium Benzoate InjectionJuly 22, 2011 Calcitriol Injection July 27, 2011 Calcium Chloride Injection August 02, 2011 Calcium Gluconate InjectionJuly 22, 2011 Capecitabine Tablets August 04, 2011 Capreomycin Injection August 04, 2011 Carboplatin Solution for Injection July 28, 2011 Cefaclor SuspensionJuly 26, 2011 Cefotetan Disodium InjectionJuly 26, 2011 Cefpodoxime July 29, 2011 Choline Magnesium Trisalicylate July 20, 2011 Chorionic Gonadotropin (Human) InjectionJuly 22, 2011 Cilostazol Tablets July 22, 2011 Ciprofloxacin Immediate-Release TabletsJuly 06, 2011 Ciprofloxacin Injection August 03, 2011 Cisplatin InjectionJune 23, 2011 Clarithromycin Immediate-Release Tablets July 29, 2011 Clevidipine Butyrate Injection July 18, 2011 Cocaine Topical Solution July 12, 2011 Cyanocobalamin Injection July 22, 2011 Cytarabine InjectionAugust 03, 2011 Dacarbazine Injection August 03, 2011 Daunorubicin Hydrochloride InjectionAugust 03, 2011 Deferoxamine Mesylate Injection June 30, 2011 Denileukin Diftitox Injection July 12, 2011 Desmopressin Injection July 08, 2011 Dexamethasone Sodium Phosphate August 04, 2011 Digoxin Immune Fab June 10, 2011 Digoxin Injection July 29, 2011 Diltiazem InjectionAugust 03, 2011 Dipyridamole InjectionAugust 03, 2011 Dopamine InjectionAugust 02, 2011 Doxorubicin InjectionJuly 20, 2011 Doxorubicin Liposomal Injection August 05, 2011 Doxycycline Hyclate InjectionJune 30, 2011 Echothiophate Powder for Ophthalmic Solution August 05, 2011 Edrophonium Injection July 27, 2011 Epinephrine Injection July 22, 2011 Ethiodized Oil June 07, 2011 Etomidate InjectionAugust 03, 2011 Etoposide Injection August 01, 2011 Famotidine InjectionAugust 04, 2011 Fluconazole Injection August 04, 2011 Fludarabine InjectionAugust 03, 2011 Fluorouracil Injection July 28, 2011 Fluphenazine Decanoate InjectionAugust 02, 2011 Fluticasone Nasal Spray July 12, 2011 Foscarnet InjectionJuly 20, 2011 Fosphenytoin InjectionJuly 22, 2011 Furosemide Injection July 27, 2011 Ganciclovir Capsules July 27, 2011 Gentamicin injection August 04, 2011 Glycopyrrolate InjectionJuly 22, 2011 Gold Sodium Thiomalate Injection August 02, 2011 Granisetron Hydrochloride Injection July 29, 2011 Haloperidol Decanoate Injection August 04, 2011 Haloperidol Lactate Injection June 17, 2011 Heparin Sodium InjectionJuly 20, 2011 Hepatitis A Virus Vaccine Inactivated July 26, 2011 Hepatitis B Vaccine Recombinant August 01, 2011 Hyaluronidase InjectionJune 17, 2011 Hydralazine Injection August 02, 2011 Hydromorphone Hydrochloride InjectionJune 03, 2011 Hydroxocobalamin Injection (Cyanokit) July 26, 2011 Ibuprofen lysine Injection July 27, 2011 Idarubicin Hydrochloride Injection August 03, 2011 Indomethacin InjectionJuly 27, 2011 Intravenous Fat Emulsion July 14, 2011 Irinotecan Injection August 03, 2011 Iron Injections July 15, 2011 Kanamycin Sulfate InjectionJune 08, 2011 Ketorolac Tromethamine InjectionJuly 15, 2011 L-Cysteine Hydrochloride Injection July 14, 2011 Labetalol InjectionAugust 04, 2011 Leflunomide Tablets August 01, 2011 Leucovorin Calcium InjectionAugust 03, 2011 Leuprolide Acetate 14-Day Kit July 22, 2011 Levofloxacin Injection August 03, 2011 Levorphanol TabletsJuly 27, 2011 Lidocaine 2% Emergency Syringes June 17, 2011 Liotrix TabletsJuly 26, 2011 Lorazepam injectable presentations July 06, 2011 Magnesium Sulfate Injection August 04, 2011 Measles, Mumps, Rubella and Varicella Virus Vaccine Live InjectionJune 07, 2011 Mechlorethamine Hydrochloride InjectionAugust 02, 2011 Mesna Injection July 27, 2011 Metaxalone Tablets July 05, 2011 Metformin Oral Solution July 12, 2011 Metformin Oral Tablets July 27, 2011 Methotrexate InjectionAugust 03, 2011 Methoxsalen Capsules and LotionJuly 26, 2011 Methylene Blue InjectionJuly 22, 2011 Methylphenidate Hydrochloride August 03, 2011 Methylprednisolone Tablets July 08, 2011 Metoclopramide InjectionJuly 22, 2011 Metoprolol InjectionJuly 29, 2011 Metronidazole Injection July 05, 2011 Metronidazole tablets July 26, 2011 Mexiletine CapsulesJune 10, 2011 Midazolam 1 mg/mL Injections August 04, 2011 Milrinone InjectionJuly 29, 2011 Mitomycin InjectionAugust 04, 2011 Morphine Injections July 28, 2011 Multiple Vitamins for Infusion - Adults July 14, 2011 Nalbuphine Injection August 02, 2011 Neostigmine Methylsulfate InjectionJuly 22, 2011 Nicardipine Hydrochloride InjectionJune 09, 2011 Nitroglycerin Injection July 26, 2011 Norepinephrine Injection August 03, 2011 Octreotide Injection July 21, 2011 Ondansetron Injection 2 mg/mLJuly 29, 2011 Oseltamivir Phosphate Oral Suspension July 13, 2011 Oxycodone Immediate Release Tablets and CapsulesJuly 12, 2011 Oxycodone Immediate Release Solution July 22, 2011 Paclitaxel Injection August 05, 2011 Papaverine Injection July 22, 2011 Paregoric Liquid July 01, 2011 Pentosan Polysulfate Sodium June 28, 2011 Pentoxifylline TabletsJune 17, 2011 Phentolamine InjectionAugust 03, 2011 Phenylephrine Hydrocholoride InjectionAugust 05, 2011 Phenytoin Injection July 20, 2011 Phenytoin Oral July 20, 2011 Potassium Acetate Injection July 27, 2011 Potassium Phosphate Injection August 01, 2011 Prochlorperazine Edisylate Injection August 03, 2011 Promethazine Injection July 15, 2011 Propofol InjectionJuly 19, 2011 Protamine Sulfate July 28, 2011 Rabies Immune Globulin July 13, 2011 Reteplase InjectionAugust 02, 2011 Rifampin InjectionJuly 08, 2011 Rocuronium Injection July 13, 2011 Rotigotine Transdermal Systems PatchAugust 02, 2011 Selenium Injection July 22, 2011 Sodium Acetate Injection August 04, 2011 Sodium Bicarbonate Injection July 26, 2011 Sodium Chloride Concentrated Solution for Injection July 28, 2011 Sodium Fluoride Oral DropsJuly 13, 2011 Sodium Phosphate Injection July 22, 2011 Sodium Thiosulfate Injection July 22, 2011 Streptozocin For Injection June 30, 2011 Sucralfate Oral Presentations July 26, 2011 Sulfamethoxazole/Trimethoprim InjectionJuly 26, 2011 Terbutaline Sulfate Injection July 28, 2011 Testosterone Cypionate Intramuscular Injection July 27, 2011 Thiotepa InjectionJuly 28, 2011 Thiothixene Capsules July 05, 2011 Thyrotropin Alfa July 18, 2011 Ticarcillin Clavulanate July 12, 2011 Ticlopidine Tablets June 24, 2011 Tobramycin Injection July 28, 2011 Topiramate Capsules July 26, 2011 Torsemide InjectionJuly 22, 2011 Trace Elements Injection July 22, 2011 Trazodone TabletsJuly 06, 2011 Triamterene and Hydrochlorothiazide Capsules and TabletsAugust 03, 2011 Valproate Injection July 20, 2011 Vancomycin Hydrochloride InjectionJuly 13, 2011 Vasopressin InjectionJuly 26, 2011 Vecuronium Bromide InjectionJuly 28, 2011 Vincristine InjectionJune 28, 2011 Vitamin A Injection June 23, 2011 Zinc Injection July 22, 2011 Zoster Vaccine Live July 26, 2011
__________________
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
Hugs & Blessings
Sheila
Diagnosed at age 49.99999 2/21/2002 via Mammography (Calcifications)
Core Biopsy 2/22/02
L. Mastectomy 2/25/2002
Stage 1, 0.7cm IDC, Node Neg from 19 nodes Her2+++ ER PR Neg
6/2003 Reconstruction W/ Tissue Expander, Silicone Implant
9/2003 Stage IV with Mets to Supraclavicular nodes
9/2003 Began Herceptin every 3 weeks
3/2006 Xeloda 2500mg/Herceptin for recurrence to neck nodes
3/2007 Added back the Xeloda with Herceptin for continued mets to nodes
5/2007 Taken Off Xeloda, no longer working
6/14/07 Taxol/Herceptin/Avastin
3/26 - 5/28/08 Taxol Holiday Whopeeeeeeeee
5/29 2008 Back on Taxol w Herceptin q 2 weeks
4/2009 Progression on Taxol & Paralyzed L Vocal Cord from Nodes Pressing on Nerve
5/2009 Begin Rx with Navelbine/Herceptin
11/09 Progression on Navelbine
Fought for and started Tykerb/Herceptin...nodes are melting!!!!!
2/2010 Back to Avastin/Herceptin
5/2010 Switched to Metronomic Chemo with Herceptin...Cytoxan and Methotrexate
Pericardial Window Surgery to Drain Pericardial Effusion
7/2010 Back to walking a mile a day...YEAH!!!!
9/2010 Nodes are back with a vengence in neck
Qualified for TDM-1 EAP
10/6/10 Begin my miracle drug, TDM-1
Mixed response, shrinking internal nodes, progression skin mets after 3 treatments
12/6/10 Started Halaven (Eribulen) /Herceptin excellent results in 2 treatments
2/2011 I CELEBRATE my 9 YEAR MARK!!!!!!!!!!!!!
7/5/11 begin Gemzar /Herceptin for node progression
2/8/2012 Gemzar stopped, Continue Herceptin
2/20/2012 Begin Tomo Radiation to Neck Nodes
2/21/2012 I CELEBRATE 10 YEARS
5/12/2012 BeganTaxotere/ Herceptin is my next miracle for new node progression
6/28/12 Stopped Taxotere due to pregression, Started Perjeta/Herceptin
Last edited by Sheila; 08-07-2011 at 06:15 AM..
|
|
|
08-07-2011, 07:05 AM
|
#2
|
Senior Member
Join Date: Sep 2005
Location: france
Posts: 1,648
|
Re: List of Drugs in Short Supply...Xeloda, Cisplatin
could this be the problem:
Shortchanging Cancer Patients
By EZEKIEL J. EMANUEL
Ezekiel J. Emanuel is an oncologist and former White House adviser who will be a professor of medical ethics and health policy at the University of Pennsylvania beginning in September. He will be contributing regularly to Op-Ed.
RIGHT now cancer care is being rationed in the United States.
Probably to their great disappointment, President Obama’s critics cannot blame this rationing on death panels or health care reform. Rather, it is caused by a severe shortage of important cancer drugs.
Of the 34 generic cancer drugs on the market, as of this month, 14 were in short supply. They include drugs that are the mainstay of treatment regimens used to cure leukemia, lymphoma and testicular cancer. As Dr. Michael Link, the president of the American Society of Clinical Oncology, recently told me, “If you are a pediatric oncologist, you know how to cure 70 to 80 percent of patients. But without these drugs you are out of business.”
This shortage is even inhibiting research studies that can lead to higher cure rates: enrollment of patients in many clinical trials has been delayed or stopped because the drugs that are in short supply make up the standard regimens to which new treatments are added or compared.
The sad fact is, there are plenty of newer brand-name cancer drugs that do not cure anyone, but just extend life for a few months, at costs of up to $90,000 per patient. Only the older but curative cancer drugs — drugs that can cost as little as $3 per dose — have become unavailable. Most of these drugs have no substitutes, but, crazy as it seems, in some cases these shortages are forcing doctors to use brand-name drugs at more than 100 times the cost.
Only about 10 percent of the shortages can be attributed to a lack of raw materials and essential ingredients to manufacture the drugs. Most shortages appear instead to be the consequence of corporate decisions to cease production, or interruptions in production caused by money or quality problems, which manufacturers do not appear to be in a rush to fix.
If the laws of supply and demand were working properly, a drug shortage would cause a price rise that would induce other manufacturers to fill the gap. But such laws do not really apply to cancer drugs.
The underlying reason for this is that cancer patients do not buy chemotherapy drugs from their local pharmacies the way they buy asthma inhalers or insulin. Instead, it is their oncologists who buy the drugs, administer them and then bill Medicare and insurance companies for the costs.
Historically, this “buy and bill” system was quite lucrative; drug companies charged Medicare and insurance companies inflated, essentially made-up “average wholesale prices.” The Medicare Prescription Drug, Improvement and Modernization Act of 2003, signed by President George W. Bush, put an end to this arrangement. It required Medicare to pay the physicians who prescribed the drugs based on a drug’s actual average selling price, plus 6 percent for handling. And indirectly — because of the time it takes drug companies to compile actual sales data and the government to revise the average selling price — it restricted the price from increasing by more than 6 percent every six months.
The act had an unintended consequence. In the first two or three years after a cancer drug goes generic, its price can drop by as much as 90 percent as manufacturers compete for market share. But if a shortage develops, the drug’s price should be able to increase again to attract more manufacturers. Because the 2003 act effectively limits drug price increases, it prevents this from happening. The low profit margins mean that manufacturers face a hard choice: lose money producing a lifesaving drug or switch limited production capacity to a more lucrative drug.
The result is clear: in 2004 there were 58 new drug shortages, but by 2010 the number had steadily increased to 211. (These numbers include noncancer drugs as well. )
Unfortunately, there is no quick fix, because all solutions require legislation. A bill introduced in February by Senator Amy Klobuchar, Democrat of Minnesota, and Senator Bob Casey, Democrat of Pennsylvania, would require generic manufacturers to notify the Food and Drug Administration if they expected a supply problem or planned to stop manufacturing a drug. But the F.D.A. isn’t able to force manufacturers to produce a drug, and learning about impending shortages with little authority to alleviate them is of limited benefit. Indeed, early warning could exacerbate the problem: the moment oncologists or cancer centers hear there is going to be a shortage of a critical drug, their response could well be to start hoarding.
You don’t have to be a cynical capitalist to see that the long-term solution is to make the production of generic cancer drugs more profitable. Most of Europe, where brand-name drugs are cheaper than in the United States, while generics are slightly more expensive, has no shortage of these cancer drugs.
One solution would be to amend the 2003 act to increase the amount Medicare pays for generic cancer drugs to the average selling price plus, say, 30 percent, after the drugs have been generic for three years. This would encourage the initial rapid price drop that makes generics affordable, but would allow for an increase in price and profits to attract more generic producers and the fixing of any manufacturing problems that subsequently arose.
Increasing the price for generic oncology drugs would have a negligible impact on overall health care costs. Total spending on generic injectable cancer drugs was $400 million last year — just 2 percent of cancer drug costs, and less than 0.5 percent of the total cost of cancer care. If we are worried about costs, we could follow Europe and pay for the higher prices by lowering what Medicare pays for the brand-name drugs that extend life by only a few months.
A more radical approach would be to take Medicare out of the generic cancer drug business entirely. Once a drug becomes generic, Medicare should stop paying, and it should be covered by a private pharmacy plan. That way prices can better reflect the market, and market incentives can work to prevent shortages.
Scare-mongering about death panels and health care reform has diverted attention from real issues in our health care system. Shortages in curative cancer treatments are completely unacceptable. We need to stop the political demagoguery and fix the real rationing problem.
__________________
|
|
|
08-07-2011, 08:22 AM
|
#3
|
Senior Member
Join Date: Oct 2005
Posts: 3,519
|
Re: List of Drugs in Short Supply...Xeloda, Cisplatin
Thanks Sheila... it's a shame for this to be happening. Welcome to the future, unless corrections can be made swiftly.
As one who has a visceral distrust of Zeke Emanuel, here's what I have been reading about this:
The Disturbing Rise in Drug Shortages:
A “Multifactorial” Problem
June 10, 2011 by Kate Greenwood
With the Annual Meeting of the American Society of Clinical Oncology this past week came a wave of news stories about cancer and cancer treatment. Frank Pasquale highlights a disturbing warning issued by oncologists at the meeting, that “cancer medicines desperately needed by sick children and adults are in short supply, undermining the ability of U.S. doctors to administer treatments.” Supplies of other medicines are running short, too, including treatments for anaphylactic shock, attention deficit hyperactivity disorder, cardiac arrest, cystic fibrosis, and infertility.
Writing for the AP, Lauran Neergaard reports that “[t]he problem of scarce supplies or even completely unavailable medications isn’t a new one but it’s getting markedly worse.” According to Lancet Oncology, there were a record 211 drug shortages in 2011, up from 166 in 2009, 149 in 2008, 129 in 2007, and 70 in 2006. Neergard adds that “another 89 drug shortages have occurred in the first three months of this year[.]”
Most of the medicines that have run short are sterile injectable drugs, which are complex and time-consuming to manufacture. (The anesthesia drug sodium thiopental which I blogged about here falls into this category.) And, most, or even all, of the shortfall drugs are no longer subject to protection from a patent or Food & Drug Administration-administered exclusivity period, so the innovator firms that developed them are subject to competition from generic manufacturers. The resultant lower prices and slimmer profit margins mean that, in the words of leading oncologist Dr. Richard Schilsky, the manufacturers’ return on investment is “pretty low.”
Among the reasons cited for the rise in drug shortages are the inherent challenges of manufacturing sterile injectable drugs, the low return on investment facing generic manufacturers, which has led the number of manufacturers of any given generic drug to dwindle, drug company mergers, which can result in the discontinuation of one of two similar products, the time it takes the FDA to approve applications to make manufacturing changes, for example a change in the source of a drug’s active ingredient, and the failure of the FDA to act expeditiously in investigating manufacturing problems and clearing plants to resume production once the problems have been resolved.
The Preserving Access to Lifesaving Medications Act, introduced in February by Senators Robert Casey and Amy Klobuchar, would require manufacturers to notify FDA “of a discontinuance, interruption, or other adjustment of the manufacture of the drug that would likely result in a shortage of such drug[.]“ Per Lauran Neergard, the FDA “was able to prevent 38 close calls from turning into shortages last year by speeding approval of manufacturing changes or urging competing companies to get ready to meet a shortfall.” The FDA has even permitted (temporarily) the import of medicines approved outside the United States when necessary to mitigate shortages.
Participants in a Drug Shortages Summit convened late last year by the American Society of Clinical Oncology and others recommended that additional legislative and regulatory reforms be explored, ranging from providing incentives to manufacturers in exchange for a guarantee that they continue producing critical drugs, to charging manufacturers fees to fund expedited FDA review of applications for permission to manufacture generic drugs, to requiring manufacturing redundancies (e.g. that more than one source for a drug’s active ingredient be identified) as a condition of approval. Interestingly, while some participants in the Drug Shortages Summit argued that products liability exposure could cause companies to withdraw drugs from the market, the manufacturers who attended denied this, calling the decision “multifactorial.” There is evidence to support the manufacturers’ claim. As I discussed here, in late 2004, after Chiron Corporation announced that it would not be able to provide flu vaccine for the United States market that year due to manufacturing issues, Congress brought the flu vaccine into the Vaccine Injury Compensation Program fold. Unfortunately, liability relief did not result in an increase in the number of manufacturers in the flu vaccine market. Targeted reforms like those that the Summit participants recommend be explored seem more likely to be effective at ensuring a steady, reliable supply of vital medicines.
__________________
Brenda
NOV 2012 - 9 yr anniversary
JULY 2012 - 7 yr anniversary stage IV (of 50...)
Nov'03~ dX stage 2B
Dec'03~ Rt side mastectomy, Her2+, ER/PR+, 10 nodes out, one node positive
Jan'04~ Taxotere/Adria/Cytoxan x 6, NED, no Rads, Tamox. 1 year, Arimadex 3 mo., NED 14 mo.
Sept'05~ micro mets lungs/chest nodes/underarm node, Switched to Aromasin, T/C/H x 7, NED 6 months - Herceptin only
Aug'06~ micro mets chest nodes, & bone spot @ C3 neck, Added Taxol to Herceptin
Feb'07~ Genetic testing, BRCA 1&2 neg
Apr'07~ MRI - two 9mm brain mets & 5 punctates, new left chest met, & small increase of bone spot C3 neck, Stopped Aromasin
May'07~ Started Tykerb/Xeloda, no WBR for now
June'07~ MRI - stable brain mets, no new mets, 9mm spots less enhanced, CA15.3 down 45.5 to 9.3 in 10 wks, Ty/Xel working magic!
Aug'07~ MRI - brain mets shrunk half, NO NEW BRAIN METS!!, TMs stable @ 9.2
Oct'07~ PET/CT & MRI show NED
Apr'08~ scans still show NED in the head, small bone spot on right iliac crest (rear pelvic bone)
Sept'08~ MRI shows activity in brain mets, completed 5 fractions/5 consecutive days of IMRT to zap the pesky buggers
Oct'08~ dropped Xeloda, switched to tri-weekly Herceptin in combo with Tykerb, extend to tri-monthly Zometa infusion
Dec'08~ Brain MRI- 4 spots reduced to punctate size, large spot shrunk by 3mm, CT of torso clear/pelvis spot stable
June'09~ new 3-4mm left cerrebellar spot zapped with IMRT targeted rads
Sept'09~ new 6mm & 1 cm spots in pituitary/optic chiasm area. Rx= 25 days of 3D conformal fractionated targeted IMRT to the tumors.
Oct'09~ 25 days of low dose 3D conformal fractionated targeted IMRT to the bone mets spot on rt. iliac crest that have been watching for 2 years. Added daily Aromasin back into treatment regimen.
Apr'10~ Brain MRI clear! But, see new small spot on adrenal gland. Change from Aromasin back to Tamoxifen.
June'10~ Tumor markers (CA15.3) dropped from 37 to 23 after one month on Tamoxifen. Continue to monitor adrenal gland spot. Remain on Tykerb/Herceptin/Tamoxifen.
Nov'10~ Radiate positive mediastinal node that was pressing on recurrent laryngeal nerve, causing paralyzed larynx and a funny voice.
Jan'11~ MRI shows possible activity or perhaps just scar tissue/necrotic increase on 3 previously treated brain spots and a pituitary spot. 5 days of IMRT on 4 spots.
Feb'11~ Enrolled in T-DM1 EAP in Denver, first treatment March 25, 2011.
Mar'11~ Finally started T-DM1 EAP in Denver at Rocky Mountain Cancer Center/Rose on Mar. 25... hallelujah.
"I would rather be anecdotally alive than statistically dead."
|
|
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
All times are GMT -7. The time now is 04:27 AM.
|